1. Moffat JG, Rudolph J, and Bailey D (2014) Phenotypic screening in cancer drug discoverypast, present and future. Nat Rev Drug Discov 13:588-602.
2. Moffat JG, Vincent F, Lee JA, et al. (2017) Opportunities and challenges in phenotypic drug discovery: An industry perspective. Nat Rev Drug Discov 16:531-543.
3. Swinney DC, and Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10:507-519.
4. Saxena C, Higgs RE, Zhen E, and Hale JE (2009) Small-molecule affinity chromatography coupled mass spectrometry for drug target deconvolution. Expert Opin Drug Discov 4:701-714.
5. Kawatani M, and Osada H (2014) Affinity-based target identification for bioactive small molecules. Medchemcomm 5:277-287.
6. Murale DP, Hong SC, Haque MM, and Lee JS (2017) Photo-affinity labeling (PAL) in chemical proteomics: A handy tool to investigate protein-protein interactions (PPIs). Proteome Sci 15:1-34.
7. Sakamoto S, and Hmachi I (2019) Recent progress in chemical modification of proteins. Anal Sci 35:5-27.
8. Sato SI, Kwon Y, Kamisuki S, et al. (2007) Polyproline-rod approach to isolating protein targets of bioactive small molecules: Isolation of a new target of indomethacin. J Am Chem Soc 129:873-880.
9. Sun J, Prabhu N, Tang J, et al. (2021). Recent advances in proteome-wide label-free target deconvolution for bioactive small molecules. Med res rev 10.1002/med.21788. Advance online publication.
10. Savitski MM, Reinhard Friedrich BM, Franken H, et al. (2014) Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346:1255784.
11. Feher M and Schmidt JM (2003) Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 43:218-27.
12. Rosén J, Gottfries J, Muresan S, et al. (2009) Novel Chemical Space Exploration via Natural Products. J Med Chem 52:1953-1962.
13. Lachance H, Wetzel S, Kumar K, and Waldmann H (2012) Charting, navigating, and populating natural product chemical space for drug discovery. J Med Chem 55:5989-6001.
14. Harvey AL, Edrada-Ebel R, and Quinn RJ (2015) The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov 14:111-129.
15. Newman DJ, and Cragg GM (2016) Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod 79:629-661.
16. Umezawa K, Ohse T, Yamamoto T, et al. (1994) Isolation of a new vinca alkaloid from the leaves of Ervatamia microphylla as an inhibitor of ras functions. Anticancer Res 14:2413-7.
17. Umezawa K, Taniguchi T, Toi M, et al. (1996) Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice. Drugs Exp Clin Res 22:35-40.
18. Umezawa K, Hiroki A, Kawakami M, et al. (2003) Induction of insulin production in rat pancreatic acinar carcinoma cells by conophylline. Biomed. Pharmacother. 57:341-50.
19. Ogata T, Li L, Yamada S, et al. (2004) Promotion of-Cell Differentiation by Conophylline in Fetal and Neonatal Rat Pancreas. Diabetes 53:2596-2602.
20. Ohashi T, Nakade Y, Ibusuki M, et al. (2019) Conophylline inhibits high fat diet-induced nonalcoholic fatty liver disease in mice. PLoS One 14:e0210068.
21. Saito R, Yamada S, Yamamoto Y, et al. (2012) Conophylline suppresses pancreatic stellate cells and improves islet fibrosis in Goto-Kakizaki rats. Endocrinology 153:621-630.
22. Tezuka T, Ota A, Karnan S, Matsuura K, et al. (2018) The plant alkaloid conophylline inhibits matrix formation of fibroblasts. J Biol Chem 293:20214-20226.
23. Sasazawa Y, Sato N, Umezawa K, and Simizu S (2015) Conophylline protects cells in cellular models of neurodegenerative diseases by inducing Mammalian target of rapamycin (mTOR)- independent autophagy. J Biol Chem 290:6168-6178.
24. Ohsumi Y (2001) Molecular dissection of autophagy: two ubiquitin-like systems. (2001) Nat Rev Mol Cell Biol 2:211-6.
25. Galluzzi L, Baehrecke EH, Ballabio A, et al. (2017) Molecular definitions of autophagy and related processes. EMBO J 36:1811-1836.
26. Mizushima N (2018) A brief history of autophagy from cell biology to physiology and disease. Nat Cell Biol 20:521-527.
27. Mizushima N, and Levine B (2020) Autophagy in Human Diseases. N Engl J Med 383:1564- 1576.
28. Brigelius-Flohé R, and Maiorino M (2013) Glutathione peroxidases. Biochim Biophys Acta 1830:3289-303.
29. Yang WS, Sriramaratnam R, Welsch ME, et al. (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156:317-331.
30. Gao M, Monian P, Pan Q, et al. (2016) Ferroptosis is an autophagic cell death process. Cell Res 26:1021-1032.
31. Su LJ, Zhang JH, Gomez H, et al. (2019) Reactive Oxygen Species-Induced Lipid Peroxidation in Apoptosis, Autophagy, and Ferroptosis. Oxid Med Cell Longev 5080843.
32. Hou W, Xie Y, Song X, et al. (2016) Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12:1425-1428.
33. Wang X, Lu S, He C, et al. (2019) RSL3 induced autophagic death in glioma cells via causing glycolysis dysfunction. Biochem Biophys Res Commun 518:590-597.
34. Scheerer P, Borchert Astrid, Krauss N, et al. (2007) Structural basis for catalytic activity and enzyme polymerization of phospholipid hydroperoxide glutathione peroxidase-4 (GPx4). Biochemistry 46:9041-9.
35. Haberzettl P, and Hill BG (2013) Oxidized lipids activate autophagy in a JNK-dependent manner by stimulating the endoplasmic reticulum stress response. Redox Biol 1:56-64.
36. Wei Y, An Z, Zou Z, et al. (2015) The stress-responsive kinases MAPKAPK2/MAPKAPK3 activate starvation-induced autophagy through Beclin 1 phosphorylation. eLife 4:e05289.
37. Dolma S, Lessnick SL, Hahn WC, Stockwell BR. (2003) Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3:285-296.
38. Abe H, Kikuchi S, Hayakawa K, et al. (2011) Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate). ACS Med Chem Lett 2:320-324.
39. Yamaguchi T, Kakefuda R, Tajima N, et al. (2011) Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol 39:23-31.
40. Zheng CF and Guan KL. (1994) Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues. EMBO J 13:1123-1131.
41. Adjei AA, Cohen RB, Franklin W, et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-2146.
42. Lee L, Niu H, Goelzer P, et al. (2010) The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression. J Clin Pharmacol 50:1397-1405.
43. Nguyen TK, Jordan N, Friedberg J, et al. (2010) Inhibition of MEK/ERK 1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leuk Res 34:379-386.
44. Roberts PJ and Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. (2007) Oncogene 26:3291-3310.
45. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. (2007) Biochim Biophys Acta 1773:1263-1284.
46. Friday BB and Adjei AA. (2008) Advances in targeting the Ras/Raf/MEK/Erk mitogenactivated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14:342-346.
47. Cohen MH, Williams GA, Sridhara R, et al. (2004) United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10:1212-1218.
48. Lièvre A, Bachet JB, Le Corre D, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995.
49. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308-1324.
50. Bollag G, Hirth P, Tsai J, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599.
51. Chabner BA. (2011) Early accelerated approval for highly targeted cancer drugs. N Engl J Med 364:1087-1089.
52. Kakutani M, Takeuchi K, Waga I, et al. (1999) JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm res 48:461-468.
53. Iwamura H, Sato M, Wakitani K. (2004) Comparative study of glucocorticoids, cyclosporine A, and JTE-607 [(-)-Ethyl-N[3,5-dichloro-2-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]benzoyl]-L-phenylalaninate dihydrochloride] in a mouse septic shock model. J Pharmacol Exp Ther 311:1256-1263.
54. Sasaki J, Fujishima S, Iwamura H, et al. (2003) Prior burn insult induces lethal acute lung injury in endotoxemic mice: effects of cytokine inhibition. Am J Physiol Lung Cell Mol Physiol 284:L270-L278.
55. Jian MY, Koizumi T, Tsushima K, Kubo K. (2004) JTE-607, a cytokine release blocker, attenuates acid aspiration-induced lung injury in rats. Eur J Pharmacol 488:231-238.
56. Tajima N, Fukui K, Uesato N, et al. (2010) JTE-607, a multiple cytokine production inhibitor, induces apoptosis accompanied by an increase in p21waf1/cip1 in acute myelogenous leukemia cells. Cancer Sci 101:774-781.
57. Proudfoot NJ, Furger A, Dye MJ. (2002) Integrating mRNA processing with transcription. Cell 108:501-512.
58. Neve J, Patel R, Wang Z, et al. (2017) Cleavage and polyadenylation: Ending the message expands gene regulation. RNA Biol 14:865-890.
59. Shi Y, Di Giammartino DC, Taylor D, et al. (2009) Molecular architecture of the human premRNA 3' processing complex. Mol Cell 33:365-376.
60. Xiang K, Tong L, Manley JL. (2014) Delineating the structural blueprint of the pre-mRNA 3'- end processing machinery. Mol Cell Biol 34:1894-1910.
61. Kolev NG, Steitz JA. (2005) Symplekin and multiple other polyadenylation factors participate in 3'-end maturation of histone mRNAs. Genes Dev 19:2583-2592.
62. Mandel CR, Kaneko S, Zhang H, et al. (2006) Polyadenylation factor CPSF-73 is the premRNA 3'-end-processing endonuclease. Nature 444:953-956.
63. Sullivan KD, Steiniger M, Marzluff WF. (2009) A core complex of CPSF73, CPSF100, and Symplekin may form two different cleavage factors for processing of poly(A) and histone mRNAs. Mol Cell 34:322-332.
64. Tian B, Manley JL. Alternative polyadenylation of mRNA precursors. (2017) Nat Rev Mol Cell Biol 18:18-30.
65. Hogg JR, Goff SP. (2010) Upf1 senses 3'UTR length to potentiate mRNA decay. Cell 143:379- 389.
66. Suzuki E, Ogura H, Kato K, et al. (2009) Preparation of conophylline affinity nano-beads and identification of a target protein. Bioorganic Med Chem 17:6188-6195.
67. El-Baba TJ, Woodall DW, Raab SA, et al. (2017) Melting Proteins: Evidence for Multiple Stable Structures upon Thermal Denaturation of Native Ubiquitin from Ion Mobility Spectrometry-Mass Spectrometry Measurements. J Am Chem Soc 139:6306-6309.
68. Gaetani M, Sabatier P, Saei AA, et al. (2019) Proteome Integral Solubility Alteration: A HighThroughput Proteomics Assay for Target Deconvolution. J Proteome Res 18:4027-4037.
69. Hiramoto M, Shimizu N, Sugimoto K, et al. (1998) Nuclear targeted suppression of NF-κB activity by the novel quinone derivative E3330. J Immunol 160:810-19.